AMENDMENTS TO THE CLAIMS

1. (Pending – Once Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with [gossypol] (-)-gossypol, a physiologically acceptable salt of [gossypol] (-)-gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of [gossypol] (-)-gossypol, a physiologically acceptable salt of [gossypol] (-)-gossypol, gossypolone, and a physiologically acceptable salt of gossypolone, and a pharmaceutically acceptable carrier.

2. (Pending – Never Amended) The method of claim 1, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

3. (Pending – Never Amended) The method of claim 2, wherein said cancer is adrenal cancer.

4. (Pending – Once Amended) The method of claim 1, wherein the blood concentration of said compound is [400] 200-1000 ng/dl.

5. (Pending – Never Amended) The method of claim 4, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.

6. (Pending – Never Amended) The method of claim 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.

7. (Pending – Never Amended) The method of claim 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.

8. (Pending – Twice Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with [gossypol] (-)-gossypol, a [pharmaceutically] physiologically acceptable salt of [gossypol] (-)-gossypol, or a combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of [gossypol] (-)-gossypol and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9. (Pending – Never Amended) The method of claim 8, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

10. (Pending – Never Amended) The method of claim 8, wherein said cancer is adrenal cancer.

11. (Pending – Once Amended) The method of claim 8, wherein the blood concentration of said compound is [400] 200-1000 ng/dl.

12. (Pending – Never Amended) The method of claim 8, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

13. (Pending – Never Amended) The method of claim 8, wherein said compound is administered orally at a dose of 20-100 mg/d.

14. (Pending – Never Amended) The method of claim 8, wherein said compound is administered rectally at a dose of 40-140 mg/d.

15. (Pending – Never Amended) The method of claim 1, wherein said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

16. (Pending – Never Amended) The method of claim 8, wherein said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

17. (Pending – Never Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a physiologically acceptable salt of gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol, a physiologically acceptable salt of gossypol, gossypolone, and a physiologically acceptable salt of gossypolone, and a pharmaceutically acceptable carrier, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer, or said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

18. (Pending – Never Amended) The method of claim 17, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

19. (Pending – Never Amended) The method of claim 18, wherein said cancer is adrenal cancer.

20. (Pending – Never Amended) The method of claim 17, wherein the blood concentration of said compound is 400-1000 ng/dl.

21. (Pending – Never Amended) The method of claim 20, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.

22. (Pending – Never Amended) The method of claim 21, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d.

23. (Pending – Never Amended) The method of claim 21, wherein said

gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d.

24. (Pending – Never Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, or a combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate or breast cancer, or said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

25. (Pending – Never Amended) The method of claim 24, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

26. (Pending – Never Amended) The method of claim 25, wherein said cancer is adrenal cancer.

27. (Pending – Never Amended) The method of claim 24, wherein the blood concentration of said compound is 400-1000 ng/dl.

28. (Pending – Never Amended) The method of claim 24, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

29. (Pending – Never Amended) The method of claim 24, wherein said compound is administered orally at a dose of 20-100 mg/d.

30. (Pending – Never Amended) The method of claim 24, wherein said compound is administered rectally at a dose of 40-140 mg/d.